Exchange: NASDAQ·Updated 07:30 PM EDT

IRMD News

News
all
press releases
iRadimed Becomes Oversold
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics strong fundamentals and a valuation that looks inexpensive...
Nasdaq News: Markets
More News
IRadimed (IRMD) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Replacement Cycle Anchors IRadimed Corp.'s (IRMD) Long Term Growth
Replacement Cycle Anchors IRadimed Corp.'s (IRMD) Long Term Growth...
Yahoo! Finance: News
IRADIMED's CEO Is Selling Steadily The Plan, Not the Stock, Is Driving It
Key PointsCEO Roger E. Susi sold 7,500 shares indirectly for a transaction value of approximately $691,000...
Nasdaq News: Markets
Iradimed's CEO and Founder Sold 7,500 Company Shares. What Does That Mean for Investors?
Key PointsCEO and company founder Roger Susi sold 7,500 indirectly-held shares for a total transaction value of ~$657,000 at a weighted average price of around $87.64 per share on May 18 and May 19, 2026...
Nasdaq News: Markets
iRadimed (NASDAQ:IRMD) CEO Sells $321,337.50 in Stock
iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 3,750 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $85.69, for a total value of $321,337.50. Following the transaction, the chief executive officer directly owned...
MarketBeat
Company News for May 4, 2026
Companies in The News Are: NWL,CL,EL,IRMD
Zacks
iRadimed (NASDAQ:IRMD) Issues Earnings Results, Beats Estimates By $0.03 EPS
iRadimed (NASDAQ:IRMD - Get Free Report) issued its earnings results on Friday. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate...
MarketBeat
iRadimed Corporation (NASDAQ:IRMD) Given Consensus Rating of "Buy" by Analysts
Shares of iRadimed Corporation (NASDAQ:IRMD - Get Free Report) have been given an average recommendation of "Buy" by the five brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, three have given a buy recom...
MarketBeat
Why Iradimed Stock Topped the Market Today
Key PointsCompounding that, it topped analyst estimates on both the top and bottom lines...
Nasdaq News: Markets

Advertisement|Remove ads.